



NERVGEN PHARMA GRANTS STOCK OPTIONS

Vancouver, Canada. April 6, 2022 – **NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF)** (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing a first-in-class *neuroreparative* drug to treat nervous system damage, announced that the Company has granted 376,000 incentive stock options to Employees and Officers exercisable at a price of \$2.06 per share for a period of 10 years and that vest equally every six months over a two-year period. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the Company’s stock option plan.

About NervGen

NervGen is restoring life’s potential by creating innovative treatments for nervous system damage due to injury or disease. The Company is initially developing treatments for Alzheimer’s disease, multiple sclerosis and spinal cord injury.

For further information, please contact:

Huitt Tracey, Corporate Communications

htracey@nervgen.com

604.537.2094

Nancy Thompson, Vorticom Public Relations

nancyt@vorticom.com

212.532.2208

Follow NervGen on Twitter (@NervgenP), LinkedIn (NervGen Pharma Corp.), and Facebook (facebook.com/nervgen/) for the latest news on the Company.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.